Beware of online adverts about treatments
The Retina UK community is sometimes targeted by adverts online or in social media, offering invasive treatments for inherited sight loss.
Search results
The Retina UK community is sometimes targeted by adverts online or in social media, offering invasive treatments for inherited sight loss.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
A new approach to treating inherited sight loss
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.